DOCSLIB.ORG

Synergistic Antibiotic Effect of Cefuroxime & Clavulanic Acid

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Synergistic Antibiotic Effect of Cefuroxime & Clavulanic Acid VOL.07 NO. 01 FEBRUARY 2019 Synergistic Antibiotic Effect of Pattern of Antimicrobial Cefuroxime & Clavulanic Acid Resistance to Escherichia Coli Combination was Far More than Prevention of Surgical Site among the Urinary Tract Infection Cefuroxime Alone against E. Coli Infections: Current Recommen- Patients in Bangladesh dations and Guidelines β-lactamase mediated resistance is the most common mechanism which renders the β-lactam antibiotics Azithromycin is a reliable Urinary tract infection (UTI) is one of the most common ineffective against bacteria including Escherichia coli. antibiotic in URTI infectious diseases in the community practice with approxi- The development of resistance has led to the wide- mately 150 million people affected in the world each year spread empirical use of higher generation cephalospor- Meropenem was Effective and accounting for nearly 25% of all infections. Among all the ins, and it is likely that the third generation cephalo- Well Tolerated in Critically Ill causative organisms Escherichia coli is the most common, sporins are also losing Infants but antimicrobial resistance becomes an alarming issue for their efficacy by the same UTI management now a days. An observational study was mechanism. A study was Ceftibuten is as effective as conducted from February 2017 to January 2018 in the The zones of conducted to evaluate the amoxicillin/clavulanate in the district of Jashore, inhibition antimicrobial effect of treatment of acute exacerbations Bangladesh to assess the surrounding the Escherichia coli is cefuroxime with and of chronic bronchitis pattern of antimicrobial disks containing without a β-lactamase the most common resistance to E coli among both cefuroxime inhibitor named clavulan- causative organ- the UTI patients. A total ic acid, against E. coli. of 696 eligible patients of and clavulanic ism in UTI but Clavulanic acid is both sexes whose urine acid were larger antimicrobial naturally occurring potent culture grown E coli were than those resistance inhibitor of β-lactamase included in the study. containing cefuro- obtained by, fermentation becomes an Patients with UTI caused xime alone. from streptomyces alarming issue by other than E coli, clavuligerus. It is a female during menstrua- “suicidal inhibitor” of tion, pregnancy, history of β-lactamases produced by a wide range of Gram taking antibiotics within last 21 days, catheterization within positive and Gram negative micro-organisms. An 1 month and pelvic organ & genito urinary tract surgery institution based analytic observational study was within 6 months were excluded from the study. Evaluation carried out at Department of Microbiology, Khyber of antimicrobial resistance was done according to the Medical College, Peshawar. β-lactamase producing standard bacteriological methods. Mean age of the study Escherichia. coli were identified and cultured in cases was 41.46±17.21 years with the range from 15 to 91 Mueller Hinton medium in petri dishes. The antibiotic years. More than 85% participants were female with a sex disks containing cefuroxime alone and in combination ratio of 8:1.5. Reproductive age group ranged from 21 to 50 ....see ROLL page 2 ....see ROLL page 2 Azithromycin is a reliable antibiotic treatment in upper respiratory tract infections Page-4 diagnosis before treatment (at the inclusion), at the 4th day (end of the therapy) and at the 12th (end of the study). In this study azithromycin led to the relief of symptoms after three days in 93.6 % of patients. Antibiotics were prescribed within one year before inclusion in 56.6 % of patients and 20.5 % were previously treated with macrolides. Clinical effectiveness in study population was Azithromycin is a reliable antibiotic treatment in upper 95.6 %. Overall, 38 (9.1 %) patients reported 48 adverse events. The respiratory tract infections, giving fast resolution of symptoms most common were: abdominal pain in 14 patients (1.1 %) , diarrhea in with little adverse events in patients with presumed bacterial 12 (0.9 %), nausea in 5 (0.4 %), vomiting in 5 (0.4 %). The results of infections. this study show that azithromycin in the treatment of upper respiratory tract infections has a high clinical effectiveness and small number of adverse events. So, based on the study, Azithromycin is a reliable antibiotic treatment in upper respiratory tract infections, giving fast resolution of symptoms with little adverse events in patients with presumed bacterial infections. Meropenem was Effective Pattern of Antimicrobial Cefuroxime And Clavulanic and Well Tolerated in Resistance to Escherichia Acid Combination Was More Critically Ill Infants Coli than Cefuroxime Alone From Page-4 From Page-1 From Page-1 in the study, 99 (50%) experienced an adverse event, years was affected most commonly which constituted with clavulanic acid were placed in the same petri and 34 (17%) had serious adverse events; but no approximately two-thirds of the study population.The dishes about 24-30 mm apart. The zones of inhibition adverse events were probably or definitely related to study revealed that the maximum antimicrobial were measured according to NCCLs (National meropenem. The most commonly reported adverse resistance to E coli was Cotrimoxazole (95.0%), Committee for Clinical Laboratory standards) events were sepsis (6%), seizures (5%), elevated followed by Ceftazidime (75.7%), Gentamicin Standards) zone diameter criteria using disk diffusion conjugated bilirubin (5%), and hypokalemia (5%). (70.3%), Amikacin (69.0%), Imipenam (58.9 %,), method. A total of 40 β-lactamase producing bacteria Only 2 of the serious adverse events were deter- Cefixime (58.0%), Ciprofloxacin (57.3%), Azithro- were isolated. The zones of inhibition surrounding the mined to be possibly related to meropenem (isolated mycin (56.0%), Cefuroxime (46.6%), Cefotaxime disks containing both cefuroxime and clavulanic acid ileal perforation and an episode of fungal sepsis). (37.4%), Ceftriaxone (35.2%), Meropenem (32.2%), were larger than those containing cefuroxime alone. Effectiveness was evaluable in 192 (96%) subjects, and Nitrofurantion (4.7%). So, high magnitude of So, in this study it was found that the synergistic and overall treatment success was 84%. So, this antimicrobial resistance against Escherichia coli was antibacterial effect of the combination of cefuroxime study found that, meropenem was well tolerated in observed among the UTI patients in Bangladesh even and clavulanic acid was far more than the cefuroxime critically ill infants, and the majority of infants with extended generation of Cephalosporins, Carbap- alone against Escherichia coli. treated with meropenem met the definition of enems, Ciprofloxacin, Cotrimoxazole, Azithromycin therapeutic success. and Aminoglycosides. Antibiotics resistance depends on the genetic mutation and locality. So, geographical variation may be a determinant of difference magni- tude of antimicrobial resistance pattern. Prevention of Surgical Site Infections: Current Recommendations and Guidelines Postoperative/Posthospital CriteriaWHO ACS CDC Surgical SAP administration after comple- No evidence that prophylactic antibiot- Additional prophylactic antibiotic tion of the operation is not recom- ic administration after incision closure antimicrobial agent doses prophylaxis mended the purpose of preventing decreases SSI risk should not be administered (SAP) prolon- SSI Prophylactic antibiotics should be after the surgical incision is closed in the operating room, gation Perioperative SAP should not be discontinued at time of incision closure even in the presence of a drain continued in the presence of a (exceptions include implant-based breast wound drain solely for the reconstruction, joint arthroplasty, and purpose of preventing SSI cardiac precedures where optimal duration of antibiotic therapy remains unknown) Wound Do not use advanced dressings Mupirocin topical antibiotic applica- Do not apply antimicrobial Care over a standard dressing on tion can decrease SSI compared with a agents (i.e., ointmints, primarily closed surgical standard dressing. solutions, or powders) to the wounds for the purpose of Topical antibiotics can reduce SSI for surgical incision for the preventing SSI specific cases, including spine surgery, prevention of SSI total joint arthroplasty, and cataract surgery, but there is insufficient evidence to recommend routine use at this time Postoperative No recommendations/not Early showering (12 hours postopera- No recommendations/not Showering addressed tively) does not increase the risk of addressed SSI Postoperative Prevention of Surgical Site Infections According to NICE Guideline Changing dressings Use an aseptic non-touch technique for changing or removing surgical wound dressings. Postoperative cleansing Use sterile saline for wound cleansing up to 48 hours after surgery. Advise patients that they may shower safely 48 hours after surgery. Use tap water for wound cleansing after 48 hours if the surgical wound has separated or has been surgically opened to drain pus. Topical antimicrobial agents for wound healing by primary intention Do not use topical antimicrobial agents for surgical wounds that are healing by primary intention to reduce the risk of surgical site infection. Dressings for wound healing by secondary intention Do not use Eusol and gauze, or moist cotton gauze or mercuric antiseptic solutions to manage surgical wounds that are healing by secondary intention. Use an appropriate interactive dressing to manage surgical wounds that arehealing
Load more

Recommended publications
  • Medical Review(S) Clinical Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 200327 Priority or Standard Standard Submit Date(s) December 29, 2009 Received Date(s) December 30, 2009 PDUFA Goal Date October 30, 2010 Division / Office Division of Anti-Infective and Ophthalmology Products Office of Antimicrobial Products Reviewer Name(s) Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD Review Completion October 29, 2010 Date Established Name Ceftaroline fosamil for injection (Proposed) Trade Name Teflaro Therapeutic Class Cephalosporin; ß-lactams Applicant Cerexa, Inc. Forest Laboratories, Inc. Formulation(s) 400 mg/vial and 600 mg/vial Intravenous Dosing Regimen 600 mg every 12 hours by IV infusion Indication(s) Acute Bacterial Skin and Skin Structure Infection (ABSSSI); Community-acquired Bacterial Pneumonia (CABP) Intended Population(s) Adults ≥ 18 years of age Template Version: March 6, 2009 Reference ID: 2857265 Clinical Review Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD NDA 200327: Teflaro (ceftaroline fosamil) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 9 1.1 Recommendation on Regulatory Action ........................................................... 10 1.2 Risk Benefit Assessment.................................................................................. 10 1.3 Recommendations for Postmarketing Risk Evaluation and Mitigation Strategies ........................................................................................................................
    [Show full text]
  • Ceftazidime for Injection) PHARMACY BULK PACKAGE – NOT for DIRECT INFUSION
    PRESCRIBING INFORMATION FORTAZ® (ceftazidime for injection) PHARMACY BULK PACKAGE – NOT FOR DIRECT INFUSION To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibacterial drug for parenteral administration. It is the pentahydrate of pyridinium, 1-[[7-[[(2-amino-4­ thiazolyl)[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1­ azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, hydroxide, inner salt, [6R-[6α,7β(Z)]]. It has the following structure: The molecular formula is C22H32N6O12S2, representing a molecular weight of 636.6. FORTAZ is a sterile, dry-powdered mixture of ceftazidime pentahydrate and sodium carbonate. The sodium carbonate at a concentration of 118 mg/g of ceftazidime activity has been admixed to facilitate dissolution. The total sodium content of the mixture is approximately 54 mg (2.3 mEq)/g of ceftazidime activity. The Pharmacy Bulk Package vial contains 709 mg of sodium carbonate. The sodium content is approximately 54 mg (2.3mEq) per gram of ceftazidime. FORTAZ in sterile crystalline form is supplied in Pharmacy Bulk Packages equivalent to 6g of anhydrous ceftazidime. The Pharmacy Bulk Package bottle is a container of sterile preparation for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture program and are restricted to the preparation of admixtures for intravenous use. THE PHARMACY BULK PACKAGE IS NOT FOR DIRECT INFUSION, FURTHER DILUTION IS REQUIRED BEFORE USE.
    [Show full text]
  • Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and Its Application
    Infect Dis Ther (2017) 6:57–67 DOI 10.1007/s40121-016-0144-8 REVIEW Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and its Application Juwon Yim . Leah M. Molloy . Jason G. Newland Received: November 10, 2016 / Published online: December 30, 2016 Ó The Author(s) 2016. This article is published with open access at Springerlink.com ABSTRACT infections, CABP caused by penicillin- and ceftriaxone-resistant S. pneumoniae and Ceftaroline is a novel cephalosporin recently resistant Gram-positive infections that fail approved in children for treatment of acute first-line antimicrobial agents. However, bacterial skin and soft tissue infections and limited data are available on tolerability in community-acquired bacterial pneumonia neonates and infants younger than 2 months (CABP) caused by methicillin-resistant of age, and on pharmacokinetic characteristics Staphylococcus aureus, Streptococcus pneumoniae in children with chronic medical conditions and other susceptible bacteria. With a favorable and those with invasive, complicated tolerability profile and efficacy proven in infections. In this review, the microbiological pediatric patients and excellent in vitro profile of ceftaroline, its mechanism of action, activity against resistant Gram-positive and and pharmacokinetic profile will be presented. Gram-negative bacteria, ceftaroline may serve Additionally, clinical evidence for use in as a therapeutic option for polymicrobial pediatric patients and proposed place in therapy is discussed. Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 1F47F0601BB3F2DD. Keywords: Antibiotic resistance; Ceftaroline J. Yim (&) fosamil; Children; Methicillin-resistant St. John Hospital and Medical Center, Detroit, MI, Staphylococcus aureus; Streptococcus pneumoniae USA e-mail: [email protected] L.
    [Show full text]
  • CEFTIN® Tablets CEFTIN® for Oral Suspension
    PRODUCT INFORMATION CEFTIN® Tablets (cefuroxime axetil tablets) CEFTIN® for Oral Suspension (cefuroxime axetil powder for oral suspension) DESCRIPTION: CEFTIN Tablets and CEFTIN for Oral Suspension contain cefuroxime as cefuroxime axetil. CEFTIN is a semisynthetic, broad-spectrum cephalosporin antibiotic for oral administration. Chemically, cefuroxime axetil, the 1-(acetyloxy) ethyl ester of cefuroxime, is (RS)-1-hydroxyethyl (6R,7R)-7-[2-(2-furyl)glyoxylamido]-3-(hydroxymethyl)-8-oxo-5- thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, 72-(Z)-(O-methyl-oxime), 1-acetate 3-carbamate. Its molecular formula is C20H22N4O10S, and it has a molecular weight of 510.48. Cefuroxime axetil is in the amorphous form and has the following structural formula: CEFTIN Tablets are film-coated and contain the equivalent of 125, 250, or 500 mg of cefuroxime as cefuroxime axetil. CEFTIN Tablets contain the inactive ingredients colloidal silicon dioxide, croscarmellose sodium, FD&C Blue No. 1 (250- and 500-mg tablets only), hydrogenated vegetable oil, hydroxypropyl methylcellulose, methylparaben, microcrystalline cellulose, propylene glycol, propylparaben, sodium benzoate (125-mg tablets only), sodium lauryl sulfate, and CEFTIN® Tablets (cefuroxime axetil tablets) CEFTIN® for Oral Suspension (cefuroxime axetil powder for oral suspension) titanium dioxide. CEFTIN for Oral Suspension, when reconstituted with water, provides the equivalent of 125 mg or 250 mg of cefuroxime (as cefuroxime axetil) per 5 mL of suspension. CEFTIN for Oral Suspension contains the inactive ingredients povidone K30, stearic acid, sucrose, and tutti-frutti flavoring. CLINICAL PHARMACOLOGY: Absorption and Metabolism: After oral administration, cefuroxime axetil is absorbed from the gastrointestinal tract and rapidly hydrolyzed by nonspecific esterases in the intestinal mucosa and blood to cefuroxime.
    [Show full text]
  • Antibiotic Review
    8/28/19 Disclosure 2 E. Monee’ Carter-Griffin DNP, MA, RN, ACNP-BC Antibiotic has no financial relationships with commercial Review interests to disclose. Any unlaBeled and/or E. Monee’ Carter-Griffin, DNP, MA, RN, ACNP-BC unapproved uses of drugs or products will Be Associate Chair for Advanced Practice Nursing disclosed. University of Texas at Arlington, College of Nursing & Health Innovation Dallas Pulmonary & Critical Care, PA • Identify the general characteristics of • SusceptiBility à determine which antibiotics. antibiotics a bacteria is sensitive to • Discuss the mechanism of action, • à pharmacokinetics, and spectrum of activity MIC lowest concentration of drug that inhiBits growth of the Bacteria for the most common antiBiotic drug classes. Antibiotic Objectives • Identify commonly prescriBed antiBiotics • Trough à lowest concentration of within the drug classes including dosage Lingo drug in bloodstream range and indication for prescribing. – Collect prior to administration of • Identify special considerations for specific drug antibiotics and/or drug classes. • Peak à highest concentration of • Practice appropriate prescriBing for common drug in bloodstream bacterial infections. • Review Basic antiBiotic stewardship 3 4 principles. • Penicillins • Bactericidal or bacteriostatic • Cephalosporins • Narrow or Broad spectrum • Carbapenems General • Can elicit allergic responses Antibiotic • MonoBactam Characteristics • Affect normal Body flora Drug Classes • Macrolides • Fluoroquinolones • Sulfonamides • Tetracyclines 5 6 1 8/28/19 • Penicillins – Natural penicillins 8 – Aminopenicillins Penicillins Penicillins – Anti-staphylococcal penicillins • Mechanism of action àbactericidal à – Anti-pseudomonal penicillins interrupts cell wall synthesis 7 • Pharmacokinetics • Spectrum of Activity – Gram positive organisms Natural – Penicillin G à mostly given IM, But Natural • Streptococcus species (e.g. S. Penicillins one variation can Be given IV Penicillins pyogenes) • Poorly aBsorBed via PO • Some enterococcus species (e.g.
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Ceftibuten (hydrate) Item No. 25334 NH2 S CAS Registry No.: 118081-34-8 N Formal Name: (6R,7R)-7-[[(2Z)-2-(2-amino-4-thiazolyl)-4-carboxy- 1-oxo-2-buten-1-yl]amino]-8-oxo-5-thia-1- O azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, dihydrate • 2H2O Synonym: SCH 39720 H N S MF: C15H14N4O6S2 • 2H2O HO FW: 446.5 H O Purity: ≥98% O N UV/Vis.: λmax: 218, 262 nm Supplied as: A crystalline solid -20°C O Storage: OH Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Ceftibuten (hydrate) is supplied as a crystalline solid. A stock solution may be made by dissolving the ceftibuten (hydrate) in the solvent of choice. Ceftibuten (hydrate) is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of ceftibuten (hydrate) in these solvents is approximately 5 and 2 mg/ml, respectively. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of ceftibuten (hydrate) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of ceftibuten (hydrate) in PBS, pH 7.2, is approximately 0.1 mg/ml. We do not recommend storing the aqueous solution for more than one day.
    [Show full text]
  • Cephalosporins Can Be Prescribed Safely for Penicillin-Allergic Patients ▲
    JFP_0206_AE_Pichichero.Final 1/23/06 1:26 PM Page 106 APPLIED EVIDENCE New research findings that are changing clinical practice Michael E. Pichichero, MD University of Rochester Cephalosporins can be Medical Center, Rochester, NY prescribed safely for penicillin-allergic patients Practice recommendations an allergic reaction to cephalosporins, ■ The widely quoted cross-allergy risk compared with the incidence of a primary of 10% between penicillin and (and unrelated) cephalosporin allergy. cephalosporins is a myth (A). Most people produce IgG and IgM antibodies in response to exposure to ■ Cephalothin, cephalexin, cefadroxil, penicillin1 that may cross-react with and cefazolin confer an increased risk cephalosporin antigens.2 The presence of of allergic reaction among patients these antibodies does not predict allergic, with penicillin allergy (B). IgE cross-sensitivity to a cephalosporin. ■ Cefprozil, cefuroxime, cefpodoxime, Even penicillin skin testing is generally not ceftazidime, and ceftriaxone do not predictive of cephalosporin allergy.3 increase risk of an allergic reaction (B). Reliably predicting cross-reactivity ndoubtedly you have patients who A comprehensive review of the evidence say they are allergic to penicillin shows that the attributable risk of a cross- U but have difficulty recalling details reactive allergic reaction varies and is of the reactions they experienced. To be strongest when the chemical side chain of safe, we often label these patients as peni- the specific cephalosporin is similar to that cillin-allergic without further questioning of penicillin or amoxicillin. and withhold not only penicillins but Administration of cephalothin, cepha- cephalosporins due to concerns about lexin, cefadroxil, and cefazolin in penicillin- potential cross-reactivity and resultant IgE- allergic patients is associated with a mediated, type I reactions.
    [Show full text]
  • Assessment of the Palatability of Antibiotic Oral Suspensions: a Literature Review S
    Assessment of the palatability of antibiotic oral suspensions: a literature review S. ROBERT1, Y-E NISSE1, B. DEMORE1,2 4CPS-205 1 Pharmacie, CHRU Nancy, Nancy, France ; 2 APEMAC, Université de Lorraine, Nancy, France Corresponding author: [email protected] Background Non adherence to a full course of antibiotic occurs in approximately one-quarter of paediatric patients. The child’s refusal to take the drug is the second most common reason for non-adherence. Palatability is the third most important antibiotic feature for parents after effectiveness and safety Objective Review the literature for assessments of the palatability of antibiotic oral suspensions to inform physicians in their daily practice and consequently improve adherence Materials & methods Research date Inclusion criteria Results reporting august 2019 study reporting an assessment of palatability lowest score = poor palatability of one or more antibiotic suspensions highest score = excellent palatability Database with any assessment scale pubMed Database Data extracted all results are expressed on a 10-point scale for comparison purposes Population study characteristics population demographics separate averages were calculated for adults and/or children palatability assessments adults and children Results Palatability of antibiotic oral suspensions in children and adults Study characteristics Adults Children 9 9 studies identified 8 8 only blind studies 7 7 9/10 with healthy volunteers 6 6 5 5 4 4 3 3 2 adults only children only 2 1 1 SU RIF CLI FA LEX SXT CLR CEC ERY CTB CPR LZD CPD LOR DCX CFM LEX OXA CLR CXM ERY AMP CPR AMX AZM AMC CPD DCX CDR CFM CXM AMX AZM AMC PEN V PEN VK ERY/SU ERY/SU For a given antibiotic, each bar represents a study.
    [Show full text]
  • A Thesis Entitled an Oral Dosage Form of Ceftriaxone Sodium Using Enteric
    A Thesis entitled An oral dosage form of ceftriaxone sodium using enteric coated sustained release calcium alginate beads by Darshan Lalwani Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Master of Science Degree in Pharmaceutical Sciences with Industrial Pharmacy Option _________________________________________ Jerry Nesamony, Ph.D., Committee Chair _________________________________________ Sai Hanuman Sagar Boddu, Ph.D, Committee Member _________________________________________ Youssef Sari, Ph.D., Committee Member _________________________________________ Patricia R. Komuniecki, PhD, Dean College of Graduate Studies The University of Toledo May 2015 Copyright 2015, Darshan Narendra Lalwani This document is copyrighted material. Under copyright law, no parts of this document may be reproduced without the expressed permission of the author. An Abstract of An oral dosage form of ceftriaxone sodium using enteric coated sustained release calcium alginate beads by Darshan Lalwani Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Master of Science Degree in Pharmaceutical Sciences with Industrial Pharmacy option The University of Toledo May 2015 Purpose: Ceftriaxone (CTZ) is a broad spectrum semisynthetic, third generation cephalosporin antibiotic. It is an acid labile drug belonging to class III of biopharmaceutical classification system (BCS). It can be solvated quickly but suffers from the drawback of poor oral bioavailability owing to its limited permeability through
    [Show full text]
  • Comparison Between Cefuroxime and Amoxicillin+Clavulanate in Patients
    International Journal of Surgery Science 2019; 3(1): 154-155 E-ISSN: 2616-3470 P-ISSN: 2616-3462 © Surgery Science Comparison between cefuroxime and www.surgeryscience.com 2019; 3(1): 154-155 amoxicillin+clavulanate in patients of inguinal hernia Received: 25-11-2018 Accepted: 27-12-2018 undergoing mesh hernioplasty, a randomised control Dr. Girish Pandey study Assistant Professor, Department of General Surgery, Heritage Institute of Medical Sciences, Dr. Girish Pandey Varanasi, Uttar Pradesh, India DOI: https://doi.org/10.33545/surgery.2019.v3.i1c.29 Abstract A randomized control study was conducted at Heritage Institute of Medical Sciences (HIMS) Varanasi to evaluate clinical efficacy of cefuroxime compared with amoxicillin+clavulanate for prevention of wound infection in patients undergoing open prolene - mesh hernioplasty in cases of inguinal hernia. There was minimal difference in overall wound infection rates between cefuroxime and amoxicillin+clavulanate group and side–effects in cefuroxime group were slightly less. Therefore, cefuroxime appears to be slightly more effective antibiotic for use as surgical prophylaxis. Keywords: Hernioplasty. Wound infection. Antibiotic prophylaxis. Surgical site infection Introduction Wound infection is very common problem worldwide. Surgical site Infections (SSI) are potential complications associated with any type of procedure and are among the most preventable hospital acquired infection. SSI effect on average 11% of patients undergoing a surgical procedure and second to third most frequent type of hospital acquired infection in US and Europe. At present, no country is free from the burden of diseases caused by HAI. Commonest causative organisms are staphylococci, streptococci etc. Antibiotics are used to prevent infection at surgical site.
    [Show full text]
  • Empiric Antibiotic Therapy in Urinary Tract Infection in Patients with Risk
    Bischoff et al. BMC Infectious Diseases (2018) 18:56 DOI 10.1186/s12879-018-2960-9 RESEARCH ARTICLE Open Access Empiric antibiotic therapy in urinary tract infection in patients with risk factors for antibiotic resistance in a German emergency department Sebastian Bischoff1, Thomas Walter2, Marlis Gerigk3, Matthias Ebert1 and Roger Vogelmann1* Abstract Background: The aim of this study was to identify clinical risk factors for antimicrobial resistances and multidrug resistance (MDR) in urinary tract infections (UTI) in an emergency department in order to improve empirical therapy. Methods: UTI cases from an emergency department (ED) during January 2013 and June 2015 were analyzed. Differences between patients with and without resistances towards Ciprofloxacin, Piperacillin with Tazobactam (Pip/taz), Gentamicin, Cefuroxime, Cefpodoxime and Ceftazidime were analyzed with Fisher’s exact tests. Results were used to identify risk factors with logistic regression modelling. Susceptibility rates were analyzed in relation to risk factors. Results: One hundred thirty-seven of four hundred sixty-nine patients who met the criteria of UTI had a positive urine culture. An MDR pathogen was found in 36.5% of these. Overall susceptibility was less than 85% for standard antimicrobial agents. Logistic regression identified residence in nursing homes, male gender, hospitalization within the last 30 days, renal transplantation, antibiotic treatment within the last 30 days, indwelling urinary catheter and recurrent UTI as risk factors for MDR or any of these resistances.ForpatientswithnoriskfactorsCiprofloxacinhad90%,Pip/taz88%, Gentamicin 95%, Cefuroxime 98%, Cefpodoxime 98% and Ceftazidime 100% susceptibility. For patients with 1 risk factor Ciprofloxacin had 80%, Pip/taz 80%, Gentamicin 88%, Cefuroxime 78%, Cefpodoxime 78% and Ceftazidime 83% susceptibility.
    [Show full text]
  • Veterinary Use of Antibiotics Highly Important to Human Health
    VETERINARY USE OF ANTIBIOTICS HIGHLY IMPORTANT TO HUMAN HEALTH The World Health Organization, the Food withholding periods and export and Agriculture Organization and the slaughter intervals in the case of food- World Organization for Animal Health producing animals. Where possible, are working to protect the effectiveness choices should be based on culture and of antimicrobials in the face of rapidly susceptibility testing and the narrowest increasing resistance in serious and life- spectrum drugs effective against the threatening pathogens. infection. Antimicrobial use in animals contributes Alternatives to antimicrobial use — such to the selection and spread of resistance. as changes in husbandry, management, Veterinarians must help preserve vaccination and infection prevention existing antibiotics and fight the serious and control — should also be explored public health threat of antimicrobial in each case. The overriding principle resistance. Veterinarians need to of antimicrobial prescribing is to use carefully consider how they prescribe as little as possible but as much as antibiotics, especially those that are necessary to address the infection. critical in human medicine, to help Following diagnosis, consider using preserve these lifesaving drugs for the the first line antimicrobials along with future. alternative treatment approaches. The table on the next page outlines Second line use should be limited where in a broad and general sense how possible to when susceptibility testing or veterinarians should use the antibiotics clinical results have proven that first line highly important to human medicine identified by the Australian Strategic antibiotics are not effective. and Technical Advisory Group on Third line antimicrobials are for AMR (ASTAG). Responsible use of use as a last resort.
    [Show full text]